News

Executive search firm Toft Group places Nico Pannacciulli, MD, PhD, as Executive Medical Director, Clinical Development with Intercept Pharmaceuticals in San Diego, CA

Toft Group Executive Search has placed Nico Pannacciulli, MD, PhD, as Executive Medical Director, Clinical Development with Intercept Pharmaceuticals in San Diego, California.  Dr. Pannacciulli previously worked with Amgen as Clinical Research Medical Director, Bone Therapeutic Area and was later promoted to Global Development Leader. Before working with Amgen, Dr. Pannacciulli was the Director, Cardiovascular Clinical Research at Gilead Sciences. He also worked with Bristol-Myers Squibb as their Medical Director, CV/Metabolic. Earlier in his industry career, Dr. Pannacciulli was the Associate Director, Clinical Development at Amylin.

Dr. Pannacciulli received his MD from the University of Bari, Italy and his PhD in Endocrine and Metabolic Sciences from the University of Naples, Italy.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

 

Executive search firm Toft Group places Paul Shin as Vice President, Clinical Operations with Intercept Pharmaceuticals in San Diego, CA

Toft Group Executive Search has placed Paul Shin as Vice President of Clinical Operations for Intercept Pharmaceuticals in San Diego, California. Mr. Shin was most recently Global Head of R&D Operations at Nestle Health Science. Previously, he worked with Avanir Pharmaceuticals as Vice President, Research & Development Operations, Sr. Director, Clinical Operations & Pharmacovigilance at Spectrum Pharmaceuticals, and Director, Clinical Operations & Medical Affairs at Prometheus Therapeutics & Diagnostics. Earlier in his industry career, Mr. Shin supported clinical operations for Valeant Pharmaceuticals and MDS Pharma Services.

Mr. Shin holds a B.S. in Psychobiology from the University of California, Riverside.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

Executive search firm Toft Group places R. Eric Gerber as Senior Vice President, Strategy and Corporate Development for Agilent Technologies, Inc. in Santa Clara, CA

Toft Group Executive Search has placed R. Eric Gerber as Senior Vice President, Strategy and Corporate Development with Agilent Technologies, Inc. in Santa Clara, California. Mr. Gerber was previously Vice President of Business Development at SCIEX. Before joining SCIEX, he was Senior Director of Business Development for Dionex Corporation where he headed corporate BD and strategic planning. Earlier in his career, Eric was responsible for technology incubation at Applied Biosystems and worked as a Product Manager in Varian’s chromatography division. Eric started his career as a synthetic organic chemist at Shaman Pharmaceuticals in South San Francisco.

Mr. Gerber holds a B.A. in Organic Chemistry from Reed College, Portland, Oregon.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Agilent Technologies, Inc.

Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 14,800 people worldwide.